SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
S1400D is a biomarker-driven therapeutic substudy Lung-MAP evaluate fibroblast growth factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients with squamous…
Read More